Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Wyles

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Journal of Hepatology|March 13, 2019
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infectionDavid Wyles, Ola Weiland, Betty Yao, et al.
Open Forum Infectious Diseases|January 15, 2021
Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD StudyKristina M Brooks, Jose R Castillo-Mancilla, Mary Morrow, et al.
The Journal of Antimicrobial Chemotherapy|February 23, 2022
Predictors of 007 triphosphate concentrations in dried blood spots in persons with hepatitis C and active drug or alcohol useKristina M Brooks, Jose R Castillo-Mancilla, Mary Morrow, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2017
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 StudyDavid Wyles, Norbert Bräu, Shyam Kottilil, et al.
Open Forum Infectious Diseases|February 17, 2018
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 StudiesJason Grebely, Jordan J Feld, David Wyles, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|February 28, 2025
Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of LifeThiago S Torres, Pooja T Saha, Laura Smeaton, et al.
Hepatology (Baltimore, Md.)|September 20, 2017
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trialDavid Wyles, Fred Poordad, Stanley Wang, et al.
Hepatology (Baltimore, Md.)|July 9, 2017
Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failureDavid Wyles, Heiner Wedemeyer, Ziv Ben-Ari, et al.
Open Forum Infectious Diseases|September 27, 2017
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2Jürgen K Rockstroh, Chloe Orkin, Rolando M Viani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 23, 2018
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 StudyJürgen K Rockstroh, Karine Lacombe, Rolando M Viani, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Journal of Hepatology|March 13, 2019
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infectionDavid Wyles, Ola Weiland, Betty Yao, et al.
Open Forum Infectious Diseases|January 15, 2021
Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD StudyKristina M Brooks, Jose R Castillo-Mancilla, Mary Morrow, et al.
The Journal of Antimicrobial Chemotherapy|February 23, 2022
Predictors of 007 triphosphate concentrations in dried blood spots in persons with hepatitis C and active drug or alcohol useKristina M Brooks, Jose R Castillo-Mancilla, Mary Morrow, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2017
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 StudyDavid Wyles, Norbert Bräu, Shyam Kottilil, et al.
Open Forum Infectious Diseases|February 17, 2018
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 StudiesJason Grebely, Jordan J Feld, David Wyles, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|February 28, 2025
Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of LifeThiago S Torres, Pooja T Saha, Laura Smeaton, et al.
Hepatology (Baltimore, Md.)|September 20, 2017
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trialDavid Wyles, Fred Poordad, Stanley Wang, et al.
Hepatology (Baltimore, Md.)|July 9, 2017
Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failureDavid Wyles, Heiner Wedemeyer, Ziv Ben-Ari, et al.
Open Forum Infectious Diseases|September 27, 2017
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2Jürgen K Rockstroh, Chloe Orkin, Rolando M Viani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 23, 2018
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 StudyJürgen K Rockstroh, Karine Lacombe, Rolando M Viani, et al.
Pageof 4